Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!

Range Low Price High Price Comment
30 days $1.91 $2.61 Thursday, 9th May 2024 CHRS stock ended at $2.12. This is 4.93% less than the trading day before Wednesday, 8th May 2024. During the day the stock fluctuated 7.35% from a day low at $2.11 to a day high of $2.27.
90 days $1.91 $2.87
52 weeks $1.44 $5.91

Historical Coherus BioSciences prices

Date Open High Low Close Volume
Oct 20, 2016 $29.58 $30.81 $29.48 $30.39 443 000
Oct 19, 2016 $30.31 $30.52 $29.04 $29.76 949 300
Oct 18, 2016 $29.26 $29.68 $28.68 $29.22 323 100
Oct 17, 2016 $28.25 $28.98 $27.98 $28.88 273 500
Oct 14, 2016 $28.69 $28.98 $28.11 $28.18 284 500
Oct 13, 2016 $27.51 $28.94 $27.51 $28.44 242 800
Oct 12, 2016 $28.64 $28.84 $27.49 $27.88 320 000
Oct 11, 2016 $28.68 $28.82 $27.88 $28.52 409 600
Oct 10, 2016 $27.26 $28.81 $27.26 $28.71 353 100
Oct 07, 2016 $25.15 $27.40 $25.15 $27.04 459 400
Oct 06, 2016 $25.41 $25.79 $25.05 $25.25 208 500
Oct 05, 2016 $25.39 $26.17 $25.12 $25.78 191 000
Oct 04, 2016 $25.74 $26.19 $25.26 $25.33 351 600
Oct 03, 2016 $26.43 $26.84 $24.93 $25.45 492 000
Sep 30, 2016 $26.50 $27.19 $26.00 $26.78 264 600
Sep 29, 2016 $28.86 $29.33 $26.04 $26.29 630 500
Sep 28, 2016 $31.08 $31.16 $28.75 $28.79 385 000
Sep 27, 2016 $30.23 $31.12 $29.61 $30.92 495 700
Sep 26, 2016 $30.03 $30.33 $29.58 $29.69 265 200
Sep 23, 2016 $30.75 $31.33 $30.00 $30.00 196 800
Sep 22, 2016 $30.93 $31.30 $30.21 $30.88 288 800
Sep 21, 2016 $31.62 $31.74 $29.99 $30.75 391 000
Sep 20, 2016 $30.34 $31.78 $30.00 $31.57 592 000
Sep 19, 2016 $31.20 $31.72 $29.99 $30.03 448 700
Sep 16, 2016 $30.27 $31.98 $29.83 $30.98 1 503 200
Click to get the best stock tips daily for free!

About Coherus BioSciences

Coherus BioSciences Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma ... CHRS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT